FDA Review Sought for Zipalertinib Combo in Rare Lung Cancer
A new drug application has been initiated for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC under the FDA's Real-Time Oncology Review program.
A new drug application submission has been initiated for zipalertinib combined with chemotherapy as a first-line treatment for non-small cell lung cancer driven by EGFR exon 20 insertion mutations, with the filing submitted for review under the U.S. Food and Drug Administration's Real-Time Oncology Review program, which is designed to accelerate evaluation of promising cancer therapies.
The application is supported by data from the Phase 3 REZILIENT3 clinical study, in which the zipalertinib combination regimen demonstrated the longest median progression-free survival recorded to date among patients receiving initial treatment for this specific NSCLC subtype. EGFR exon 20 insertion mutations represent a historically difficult-to-treat subset of lung cancer with limited approved options in the first-line setting.
Read more Banner Capital to Acquire Three Plastics Firms, Form Seaway Group →
The FDA's Real-Time Oncology Review pathway allows the agency to begin evaluating portions of a drug application before the formal submission is complete, potentially shortening the overall review timeline for therapies that show early promise in serious conditions. Acceptance into this program signals regulatory interest in expediting patient access if the benefit-risk profile holds.
The Phase 3 trial result marks a meaningful benchmark in a disease area where prior therapies have struggled to demonstrate durable efficacy up front, and the submission reflects growing industry focus on molecularly targeted approaches for genomically defined lung cancer populations.
Continue reading at GlobeNewswire - Industry News on Financial Services.
